Malignant ciliary body melanoma

Summary

Malignant ciliary body melanoma (MONDO:0003912) is a cancer. A subtype of ciliary body cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant ciliary body melanoma
Mondo ID	MONDO:0003912
DOID	DOID:6524
NCIT	C4558
SNOMED CT	255015006
UMLS	C0346379
MedGen	138062
GARD	0023730
Anatomy (UBERON)	UBERON:0001775
Is cancer (heuristic)	yes

Also known as: ciliary body malignant melanoma · ciliary body melanoma · ciliary body melanoma (disease) · malignant melanoma of ciliary body · malignant melanoma of the ciliary body · melanoma (disease) of ciliary body · melanoma of ciliary body · melanoma of the ciliary body

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › uveal cancer › iris cancer › ciliary body cancer › malignant ciliary body melanoma

Subtypes (4): ciliary body spindle cell melanoma, ciliary body mixed cell melanoma, intermediate cell type ciliary body melanoma, ciliary body epithelioid cell melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.